These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 9055142)

  • 21. AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain.
    Heusser K; Vitkovsky J; Schmieder RE; Schobel HP
    Auton Neurosci; 2003 Aug; 107(1):45-51. PubMed ID: 12927226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of eprosartan, a new angiotensin II receptor blocker.
    Shusterman NH
    Am Heart J; 1999 Sep; 138(3 Pt 2):238-45. PubMed ID: 10467219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical efficacy of eprosartan.
    Weber M
    Pharmacotherapy; 1999 Apr; 19(4 Pt 2):95S-101S. PubMed ID: 10213528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A dose proportionality study of eprosartan in healthy male volunteers.
    Chapelsky MC; Martin DE; Tenero DM; Ilson BE; Boike SC; Etheredge R; Jorkasky DK
    J Clin Pharmacol; 1998 Jan; 38(1):34-9. PubMed ID: 9597557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
    Ohlstein EH; Brooks DP; Feuerstein GZ; Ruffolo RR
    Pharmacology; 1997 Nov; 55(5):244-51. PubMed ID: 9399334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of eprosartan on reflex sympathetic activation in sodium restricted patients with essential hypertension.
    Vase H; Lauridsen TG; Graffe CC; Pedersen EB
    J Am Soc Hypertens; 2011; 5(5):385-94. PubMed ID: 21640689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Review of eprosartan: a new angiotensin II receptor antagonist. Summary.
    Sica DA
    Pharmacotherapy; 1999 Apr; 19(4 Pt 2):108S-109S. PubMed ID: 10213530
    [No Abstract]   [Full Text] [Related]  

  • 28. Angiotensin blockade with eprosartan: vascular and functional implications.
    Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S5-11. PubMed ID: 18093408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quality of life and cough on antihypertensive treatment: a randomised trial of eprosartan, enalapril and placebo.
    Rake EC; Breeze E; Fletcher AE
    J Hum Hypertens; 2001 Dec; 15(12):863-7. PubMed ID: 11773989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Central inhibition of AT1receptors by eprosartan--in vitro autoradiography in the brain.
    Muders F; Palkovits M; Bahner U; Kirst I; Elsner D; Jandeleit-Dahm K
    Pharmacol Res; 2001 Mar; 43(3):251-5. PubMed ID: 11401417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.
    Damsbo P; Clauson P; Marbury TC; Windfeld K
    Diabetes Care; 1999 May; 22(5):789-94. PubMed ID: 10332683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of angiotensin II receptor antagonism on the renal hemodynamic response to cardiovascular stress.
    Frank H; Schobel HP; Vitkowsky J; Schmieder RE; Heusser K
    Kidney Int; 2003 Feb; 63(2):617-23. PubMed ID: 12631126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The influence of bromfenac on the pharmacokinetics and pharmacodynamic responses to glyburide in diabetic subjects.
    Boni JP; Cevallos WH; DeCleene S; Korth-Bradley JM
    Pharmacotherapy; 1997; 17(4):783-90. PubMed ID: 9250558
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review of eprosartan: a new angiotensin II receptor antagonist. Introduction.
    Hollenberg NK
    Pharmacotherapy; 1999 Apr; 19(4 Pt 2):71S-72S. PubMed ID: 10213524
    [No Abstract]   [Full Text] [Related]  

  • 35. The clinical profile of the angiotensin II receptor blocker eprosartan.
    Hedner T
    J Hypertens Suppl; 2002 Jun; 20(5):S33-8. PubMed ID: 12184062
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men.
    Price DA; De'Oliveira JM; Fisher ND; Hollenberg NK
    Hypertension; 1997 Aug; 30(2 Pt 1):240-6. PubMed ID: 9260987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension.
    Puig JG; Mateos F; Buño A; Ortega R; Rodriguez F; Dal-Ré R
    J Hypertens; 1999 Jul; 17(7):1033-9. PubMed ID: 10419078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction.
    de la Sierra A; Ram CV
    Curr Med Res Opin; 2007 Nov; 23 Suppl 5():S1-3. PubMed ID: 18093407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eprosartan: a review of its use in the management of hypertension.
    Robins GW; Scott LJ
    Drugs; 2005; 65(16):2355-77. PubMed ID: 16266204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of eprosartan on renal function and cardiac hypertrophy in rats with experimental heart failure.
    Brodsky S; Gurbanov K; Abassi Z; Hoffman A; Ruffolo RR; Feuerstein GZ; Winaver J
    Hypertension; 1998 Oct; 32(4):746-52. PubMed ID: 9774374
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.